상세 보기
Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial
- Lee, Kyoungmin;
- Lee, Kyung-Hun;
- Kim, Dong-Wan;
- Yoon, Jeesun;
- Choi, Yoon Ji;
- ... Park, In Hae;
- 외 15명
Citations
WEB OF SCIENCE
2Citations
SCOPUS
1초록
[No abstract available]
키워드
Cancer Radiotherapy; Cancer Survival; Clinical Article; Clinical Trial (topic); Controlled Study; Drug Efficacy; Drug Safety; Female; Follow Up; Gene Mutation; High Throughput Sequencing; Human; Human Tissue; Letter; Major Clinical Study; Male; Microsatellite Instability; Middle Aged; Non Small Cell Lung Cancer; Overall Survival; Phase 2 Clinical Trial; Progression Free Survival; Solid Tumor; Treatment Response; Adverse Drug Reaction; Article; Drug Therapy; Side Effect; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor 2; Neratinib; Trastuzumab; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor 2; Neratinib; Trastuzumab; Biosimilar Agent; Adult; Breast Cancer; Cancer Chemotherapy; CANCER
- 제목
- Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial
- 저자
- Lee, Kyoungmin; Lee, Kyung-Hun; Kim, Dong-Wan; Yoon, Jeesun; Choi, Yoon Ji; Lee, Soohyeon; Kim, Ju Won; Park, Kyong Hwa; Choi, Wonyoung; Lee, Youngjoo; Ryu, Hyewon; Koo, Dong-Hoe; Lee, Yungyoo; Jeung, Hei-Cheul; Lee, Min-Young; Lee, Namsu; Kang, Myoung Joo; Lee, Jieun; Hong, Sook Hee; Kang, Eun Joo; Park, In Hae
- 발행일
- 2025-04-11
- 유형
- Letter; Early Access
- 권
- 45
- 호
- 7
- 페이지
- 841 ~ 845